Utility of a Serum Tumour Marker Panel in the Post-Operative Follow-Up of Breast Cancer Patients with Equivocal Conventional Radiological Examinations

Tumor Biology ◽  
2003 ◽  
Vol 24 (6) ◽  
pp. 275-280 ◽  
Author(s):  
Andrea Nicolini ◽  
Angelo Carpi ◽  
Paola Ferrari ◽  
Luciano Pieri
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumour Marker ◽  
Breast Cancer Patients ◽  
Marker Panel ◽  
Serum Tumour Marker ◽  
Radiological Examinations ◽  
Serum Tumour

Ca 15.3 as a Tumour Marker in Breast Cancer

1987 ◽  
Vol 2 (3) ◽  
pp. 135-142 ◽  
Author(s):  
Peter Schmidt-Rhode ◽  
Klaus-Dieter Schulz ◽  
Gerhard Sturm ◽  
Anette Raab-Frick ◽  
Helge Prinz
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Tumour Marker ◽  
Primary Treatment ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Healthy Females

CA 15.3 is an antigenic determinant associated with human mammary carcinomas. Two murine monoclonal antibodies have been raised against the determinants, and an immunoradiometric assay (IRMA-Kit, Centocor, USA) has been developed to determine the antigen levels in plasma of cancer patients. Based on the 99% confidence limit of healthy women, plasma values above 30 U/ml are considered abnormal. Plasma samples from 357 women were examined in the present study. Healthy females (n = 84) ranged below the cut-off level between < 10 and 29 U/ml. Higher values were found in 12.5% of benign breast diseases and in 23.6% of breast cancer patients, including all stages. Depending on the stage of the disease, there were elevated levels in 11% of operable breast cancer patients preoperatively, in 7% of the cases with no evidence of disease after primary treatment and in 63.5% ofpatients with disseminated mammary carcinoma. In metastasized breast cancer the frequency and the degree of abnormal titers were closely related to the extent of the metastatic disease. Follow-up examinations of 63 patients under cytotoxic therapy showed CA 15.3 changes correlating well with the clinical course in up to 90% of the antigen positive cases. The present data indicate that CA 15.3 may be useful in the surveillance of breast cancer patients. However in our study one third of the patients with metastatic breast cancer did not show any increase in CA 15.3 and must be regarded as antigen negative.

Tumour Markers - Magic or Menace?

2001 ◽  
Vol 87 (3) ◽  
pp. 148-152
Author(s):  
P Barker ◽  
S Millroy
Keyword(s):  
Breast Cancer ◽  
Hospital Setting ◽  
District General Hospital ◽  
Tumour Marker ◽  
Tumour Burden ◽  
Multi Centre Study ◽  
Serum Tumour Marker ◽  
Life Saving ◽  
Serum Tumour

AbstractBreast cancer follow-up is aimed at the detection of metastatic disease at a stage when it can still be treated. Traditionally this has been done on a symptomatic basis confirmed by UICC criteria. By inference, tumour burden by this time is likely to be high, and therefore any therapy possibly less effective.Breast Serum Tumour Marker estimation, while disease volume is still low, has been shown in a District General Hospital setting to allow early treatment and monitor efficacy of therapy. A randomised multi-centre study is essential to determine whether these investigations are sensible and life-saving or costly and confusing.

scholarly journals Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Tianli Hui ◽  
Chao Shang ◽  
Liu Yang ◽  
Meiqi Wang ◽  
Ruoyang Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cancer Patients ◽  
Invasive Breast Cancer ◽  
Breast Cancer Patients ◽  
Diabetes Group ◽  
Metformin Group

AbstractEarly reports indicate that metformin, a clinical drug administered to treat type 2 diabetes mellitus (T2DM), was found to be associated with a better prognosis of cancer. The objective of this study was retrospectively analyzed the effect of metformin on the outcomes of Chinese breast cancer patients with T2DM. A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled. According to the medication treatment, all the patients were divided as non-diabetes group, metformin group and insulin group. The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 3553 patients (median follow up of 85 months) and estimated with the Kaplan–Meier method followed by a log-rank test. Multivariate Cox proportional hazards regression model was applied. The results showed that there was a significant survival difference among non-diabetes group, metformin group and insulin group, 5-year DFS was 85.8%, 96.1%, 73.0%, and 5-year OS was 87.3%, 97.1%, 73.3% respectively (P < 0.05). Prognostic analysis showed metformin was significantly associated with better DFS and OS. Our results suggested that metformin may have a good effect on the survival of invasive breast cancer patients with T2DM.

Sign in / Sign up

Export Citation Format

Share Document